August 13, 2018 - By Kristin Houston

Investors sentiment increased to 1.11 in Q1 2018. Its up 0.20, from 0.91 in 2017Q4. It improved, as 3 investors sold Cancer Genetics, Inc. shares while 6 reduced holdings. 6 funds opened positions while 4 raised stakes. 2.70 million shares or 2.75% less from 2.78 million shares in 2017Q4 were reported.The Illinois-based Northern Tru Corporation has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Morgan Stanley holds 16,169 shares or 0% of its portfolio. Geode Limited Liability has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). 11,600 were accumulated by Spark Invest Management Ltd Llc. Perkins Cap Management reported 963,600 shares. Virtu Financial Ltd Liability Corporation accumulated 0% or 29,495 shares. Granahan Inv Ma owns 235,502 shares. Wells Fargo Mn reported 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). National Bank Of America Corporation De has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Barclays Public Limited Company has invested 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Moreover, Jacobs Levy Equity Management Incorporated has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). The New York-based Hrt Lc has invested 0.02% in Cancer Genetics, Inc. (NASDAQ:CGIX). Vanguard Group Inc holds 583,886 shares or 0% of its portfolio. Dimensional Fund Advsr Limited Partnership reported 19,866 shares. Diker Mngmt Ltd Liability invested 0.04% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX).

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.13 EPS on August, 14 before the open.They anticipate $0.03 EPS change or 18.75 % from last quarters $-0.16 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.s analysts see -18.75 % EPS growth. The stock decreased 3.22% or $0.0314 during the last trading session, reaching $0.9451. About 69,965 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 74.25% since August 13, 2017 and is downtrending. It has underperformed by 86.82% the S&P500.

Among 2 analysts covering Cancer Genetics (NASDAQ:CGIX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cancer Genetics had 3 analyst reports since April 3, 2018 according to SRatingsIntel. The firm earned Hold rating on Tuesday, April 3 by Maxim Group. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has Buy rating given on Tuesday, May 29 by H.C. Wainwright. The company was maintained on Wednesday, June 27 by H.C. Wainwright.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $26.22 million. The Companys tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

More news for Cancer Genetics, Inc. (NASDAQ:CGIX) were recently published by: Nasdaq.com, which released: Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018 on August 07, 2018. Globenewswire.coms article titled: Cancer Genetics Closes $2.625 million Convertible Note Financing and published on July 18, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Analysts See $-0.13 EPS for Cancer Genetics, Inc. (CGIX ...